RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000036.xml
PDF herunterladen
CC BY-NC-ND 4.0 · Laryngorhinootologie 2020; 99(S 01): S301-S335
DOI: 10.1055/a-1012-9420
DOI: 10.1055/a-1012-9420
Referat
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
16. März 2020 (online)
Abstract
The treatment of salivary gland diseases represents an important segment of otorhinolaryngology. The individual otorhinolaryngologist might, however, see only a few cases per year from a large variety of salivary gland diseases. Surgical and endoscopic minimal-invasive therapy concepts play a key role. Therefore, gain of knowledge cannot only be provided by prospective clinical trials but also by meta-analyses and potentially also by registry data. Many reliable indicators are established to measure the function of a diseased salivary gland or the improvement of its function after therapy. In contrast, patient-reported outcome measures (PROMs) are not sufficiently developed. It has to be demanded that these indicators are consequently used in clinical trials. Perspectively, the same indicators could also be used for quality control for the outpatient and inpatient sector in clinical routine. The framework conditions for high-quality acquisition of knowledge are given by the otorhinolaryngology specialist medical training, the obligation of life-long continuous medical education, and certified salivary gland courses. Nevertheless, the specifications of quality standards for the treatment of patients with salivary gland diseases are not well formulated. In contrast to other disciplines also addressing salivary gland diseases, otorhinolaryngology ought to develop standards with high requirements of quality of care for salivary gland diseases.
Abstract
The treatment of salivary gland diseases represents an important segment of otorhinolaryngology. The individual otorhinolaryngologist might, however, see only a few cases per year from a large variety of salivary gland diseases. Surgical and endoscopic minimal-invasive therapy concepts play a key role. Therefore, gain of knowledge cannot only be provided by prospective clinical trials but also by meta-analyses and potentially also by registry data. Many reliable indicators are established to measure the function of a diseased salivary gland or the improvement of its function after therapy. In contrast, patient-reported outcome measures (PROMs) are not sufficiently developed. It has to be demanded that these indicators are consequently used in clinical trials. Perspectively, the same indicators could also be used for quality control for the outpatient and inpatient sector in clinical routine. The framework conditions for high-quality acquisition of knowledge are given by the otorhinolaryngology specialist medical training, the obligation of life-long continuous medical education, and certified salivary gland courses. Nevertheless, the specifications of quality standards for the treatment of patients with salivary gland diseases are not well formulated. In contrast to other disciplines also addressing salivary gland diseases, otorhinolaryngology ought to develop standards with high requirements of quality of care for salivary gland diseases.
-
Literatur
- 1 Jensen JE, Schlattmann P, Guntinas-Lichius O. Inpatient Salivary Gland Surgery in Germany: A DRG-Based Nationwide Analysis, 2007–2011. Laryngorhinootologie 2016; 95: 620-626
- 2 Guntinas-Lichius O. Eingriffe an den Speicheldrüsen. In Rettinger G, Hosemann W, Hüttenbrink K-B. et al Hrsg HNO-Operationslehre. Stuttgart: Thieme; 2018
- 3 Krumpanszky HG, Kolkmann F-W, Jonitz G. et al. Zertifizierung wird Routine. Dt Aertzebl 2002; 99: 614-616
- 4 Simon C, Caballero C. Quality Assurance and Improvement in Head and Neck Cancer Surgery: From Clinical Trials to National Healthcare Initiatives. Curr Treat Options Oncol 2018; 19: 34
- 5 Birkmeyer JD, Shahian DM, Dimick JB. et al. Blueprint for a new American College of Surgeons: National Surgical Quality Improvement Program. J Am Coll Surg 2008; 207: 777-782
- 6 Bilimoria KY, Liu Y, Paruch JL. et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg 2013; 217: 833-842, e831, 833
- 7 Proctor GB. The physiology of salivary secretion. Periodontol 2000 2016 70: 11-25
- 8 Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 1987; 115: 581-584
- 9 Locker D. Xerostomia in older adults: a longitudinal study. Gerodontology 1995; 12: 18-25
- 10 Fox PC. Management of dry mouth. Dent Clin North Am 1997; 41: 863-875
- 11 Jensen JL, Barkvoll P. Clinical implications of the dry mouth. Oral mucosal diseases. Ann N Y Acad Sci 1998; 842: 156-162
- 12 Fox PC. Xerostomia: recognition and management. Dent Assist 2008; 77 18, 20 44-18, quiz 50-11
- 13 Lofgren CD, Wickstrom C, Sonesson M. et al. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health 2012; 12: 29
- 14 Sreebny LM, Valdini A. Xerostomia. Part I: Relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 1988; 66: 451-458
- 15 Ericsson Y, Hardwick L. Individual diagnosis, prognosis and counselling for caries prevention. Caries Res 1978; 12 Suppl 1 94-102
- 16 Gonzalez LM, Martinez C, Bori YFI. et al. Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy. Am J Phys Med Rehabil 2017; 96: 68-76
- 17 Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: Relationship to nonoral symptoms, drugs, and diseases. Oral Surg Oral Med Oral Pathol 1989; 68: 419-427
- 18 Lofgren CD, Isberg PE, Christersson C. Screening for oral dryness in relation to salivary flow rate addresses the need for functional tests of saliva. Oral Health Prev Dent 2010; 8: 243-252
- 19 Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res 2000; 79: 1874-1878
- 20 Watanabe M, Yamada C, Komagata Y. et al. New low-dose liquid pilocarpine formulation for treating dry mouth in Sjogren’s syndrome: clinical efficacy, symptom relief, and improvement in quality of life. J Pharm Health Care Sci 2018; 4: 4
- 21 Burghartz M, Hackenberg S, Sittel C. et al. Surgery of the major salivary glands and its impact on salivary flow-A review. Laryngoscope 2018;
- 22 Chaushu G, Dori S, Sela BA. et al. Salivary flow dynamics after parotid surgery: a preliminary report. Otolaryngol Head Neck Surg 2001; 124: 270-273
- 23 Jaguar GC, Lima EN, Kowalski LP. et al. Impact of submandibular gland excision on salivary gland function in head and neck cancer patients. Oral Oncol 2010; 46: 349-354
- 24 Min R, Zun Z, Siyi L. et al. Gland-preserving surgery can effectively preserve gland function without increased recurrence in treatment of benign submandibular gland tumour. Br J Oral Maxillofac Surg 2013; 51: 615-619
- 25 Ge N, Peng X, Zhang L. et al. Partial sialoadenectomy for the treatment of benign tumours in the submandibular gland. Int J Oral Maxillofac Surg 2016; 45: 750-755
- 26 Rapp D. Drool control: long-term follow-up. Dev Med Child Neurol 1980; 22: 448-453
- 27 Alvarenga A, Campos M, Dias M. et al. BOTOX-A injection of salivary glands for drooling. J Pediatr Surg 2017; 52: 1283-1286
- 28 Nahlieli O. Complications of traditional and modern therapeutic salivary approaches. Acta Otorhinolaryngol Ital 2017; 37: 142-147
- 29 Roland LT, Skillington SA, Ogden MA. Sialendoscopy-assisted transfacial removal of parotid sialoliths: A systematic review and meta-analysis. Laryngoscope 2017; 127: 2510-2516
- 30 Wong WK, Shetty S. The extent of surgery for benign parotid pathology and its influence on complications: A prospective cohort analysis. Am J Otolaryngol 2018; 39: 162-166
- 31 Gaillard C, Perie S, Susini B. et al. Facial nerve dysfunction after parotidectomy: the role of local factors. Laryngoscope 2005; 115: 287-291
- 32 Guntinas-Lichius O, Klussmann JP, Wittekindt C. et al. Parotidectomy for benign parotid disease at a university teaching hospital: outcome of 963 operations. Laryngoscope 2006; 116: 534-540
- 33 Herbert HA, Morton RP. Sialocele after parotid surgery: assessing the risk factors. Otolaryngol Head Neck Surg 2012; 147: 489-492
- 34 Lee CC, Chan RC, Chan JY. Predictors for Frey Syndrome Development After Parotidectomy. Ann Plast Surg 2017; 79: 39-41
- 35 Ruohoalho J, Makitie AA, Aro K. et al. Complications after surgery for benign parotid gland neoplasms: A prospective cohort study. Head Neck 2017; 39: 170-176
- 36 Stathopoulos P, Igoumenakis D, Smith WP. Partial Superficial, Superficial, and Total Parotidectomy in the Management of Benign Parotid Gland Tumors: A 10-Year Prospective Study of 205 Patients. J Oral Maxillofac Surg 2018; 76: 455-459
- 37 Windon MJ, D’Souza G, Faraji F. et al. Priorities, concerns, and regret among patients with head and neck cancer. Cancer 2019;
- 38 Mueller SA, Riggauer J, Elicin O. et al. Patients’ preferences concerning follow-up after curative head and neck cancer treatment: A cross-sectional pilot study. Head Neck 2019;
- 39 Brennan KE, Hall SF, Yoo J. et al. Routine follow-up care after curative treatment of head and neck cancer: A survey of patients’ needs and preferences for healthcare services. Eur J Cancer Care (Engl) 2019; 28: e12993
- 40 Patel N, Har-El G, Rosenfeld R. Quality of life after great auricular nerve sacrifice during parotidectomy. Arch Otolaryngol Head Neck Surg 2001; 127: 884-888
- 41 Marshall AH, Quraishi SM, Bradley PJ. Patients’ perspectives on the short- and long-term outcomes following surgery for benign parotid neoplasms. J Laryngol Otol 2003; 117: 624-629
- 42 Nitzan D, Kronenberg J, Horowitz Z. et al. Quality of life following parotidectomy for malignant and benign disease. Plast Reconstr Surg 2004; 114: 1060-1067
- 43 Beutner D, Wittekindt C, Dinh S. et al. Impact of lateral parotidectomy for benign tumors on quality of life. Acta Otolaryngol 2006; 126: 1091-1095
- 44 Galli J, Pandolfini M, Rigante M. et al. Sensory dysfunction and quality of life after great auricular nerve sacrifice during parotidectomy: our experience. J Laryngol Otol 2015; 129: 1121-1127
- 45 Gunsoy B, Vuralkan E, Sonbay ND. et al. Quality of life following surgical treatment of benign parotid disease. Indian J Otolaryngol Head Neck Surg 2013; 65: 105-111
- 46 Stenner M, Beenen F, Hahn M. et al. Exploratory study of long-term health-related quality of life in patients with surgically treated primary parotid gland cancer. Head Neck 2016; 38: 111-117
- 47 Stodulski D, Swiatkowska-Stodulska R, Mikaszewski B. et al. Health-related quality of life of parotid carcinoma patients-a comparative study with parotid adenoma patients and assessment of the influence of demographic, treatment, and pathological factors. Int J Oral Maxillofac Surg 2019; 48: 163-172
- 48 Becker C, Pfeiffer J, Lange K. et al. Health-related quality of life in patients with major salivary gland carcinoma. Eur Arch Otorhinolaryngol 2018; 275: 997-1003
- 49 Baumann I, Cerman Z, Sertel S. et al. Development and validation of the Parotidectomy Outcome Inventory 8 (POI-8). Measurement of quality of life after parotidectomy in benign diseases. HNO 2009; 57: 884-888
- 50 Chaudhary VK, Rawat DS, Tailor M. et al. Post Parotidectomy Quality of Life in Patients with Benign Parotid Neoplasm: A Prospective Study. Indian J Otolaryngol Head Neck Surg 2018; doi: https://doi.org/10.1007/s12070-018-1312-9: 1-6
- 51 Ciuman RR, Oels W, Jaussi R. et al. Outcome, general, and symptom-specific quality of life after various types of parotid resection. Laryngoscope 2012; 122: 1254-1261
- 52 Wolber P, Volk GF, Horstmann L. et al. Patient's perspective on long-term complications after superficial parotidectomy for benign lesions: Prospective analysis of a 2-year follow-up. Clin Otolaryngol 2018;
- 53 Kroll T, Finkensieper M, Sharma SJ. et al. Short-term outcome and patient satisfaction after sialendoscopy. Eur Arch Otorhinolaryngol 2013; 270: 2939-2945
- 54 Hendry J, Chin A, Swan IR. et al. The Glasgow Benefit Inventory: a systematic review of the use and value of an otorhinolaryngological generic patient-recorded outcome measure. Clin Otolaryngol 2016; 41: 259-275
- 55 Ianovski I, Morton RP, Ahmad Z. Patient-perceived outcome after sialendoscopy using the glasgow benefit inventory. Laryngoscope 2014; 124: 869-874
- 56 Meier BA, Holst R, Schousboe LP. Patient-perceived benefit of sialendoscopy as measured by the Glasgow Benefit Inventory. Laryngoscope 2015; 125: 1874-1878
- 57 Jokela J, Saarinen R, Makitie A. et al. Costs of sialendoscopy and impact on health-related quality of life. Eur Arch Otorhinolaryngol 2019; 276: 233-241
- 58 Aubin-Pouliot A, Delagnes EA, Eisele DW. et al. The Chronic Obstructive Sialadenitis Symptoms Questionnaire to assess sialendoscopy-assisted surgery. Laryngoscope 2016; 126: 93-99
- 59 Aubin-Pouliot A, Delagnes EA, Chang JL. et al. Sialendoscopy-assisted surgery and the chronic obstructive sialadenitis symptoms questionnaire: A prospective study. Laryngoscope 2016; 126: 1343-1348
- 60 Delagnes EA, Zheng M, Aubin-Pouliot A. et al. Salivary duct stenosis: Short-term symptom outcomes after sialendoscopy-assisted salivary duct surgery. Laryngoscope 2017; 127: 2770-2776
- 61 Delagnes EA, Aubin-Pouliot A, Zheng M. et al. Sialadenitis without sialolithiasis: Prospective outcomes after sialendoscopy-assisted salivary duct surgery. Laryngoscope 2017; 127: 1073-1079
- 62 Plonowska KA, Gurman ZR, Humphrey A. et al. One-year outcomes of sialendoscopic-assisted salivary duct surgery for sialadenitis without sialolithiasis. Laryngoscope 2019; 129: 890-896
- 63 Thomson WM, Chalmers JM, Spencer AJ. et al. The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health 1999; 16: 12-17
- 64 Eisbruch A, Kim HM, Terrell JE. et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 695-704
- 65 Bulut OC, Haufe S, Hohenberger R. et al. Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia. Nuklearmedizin 2018; 57: 160-167
- 66 Osailan SM, Pramanik R, Shirlaw P. et al. Clinical assessment of oral dryness: development of a scoring system related to salivary flow and mucosal wetness. Oral Surg Oral Med Oral Pathol. Oral Radiol 2012; 114: 597-603
- 67 Seror R, Ravaud P, Bowman SJ. et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 2010; 69: 1103-1109
- 68 Seror R, Theander E, Bootsma H. et al. Outcome measures for primary Sjogren’s syndrome: a comprehensive review. J Autoimmun 2014; 51: 51-56
- 69 Hijjaw O, Alawneh M, Ojjoh K. et al. Correlation between Xerostomia index, Clinical Oral Dryness Scale, and ESSPRI with different hyposalivation tests. Open Access Rheumatol 2019; 11: 11-18
- 70 Bowman SJ, Booth DA, Platts RG. et al. Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren’s syndrome. J Rheumatol 2003; 30: 1259-1266
- 71 Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988; 3: 73-78
- 72 Reid SM, Johnson HM, Reddihough DS. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol 2010; 52: e23-e28
- 73 Rashnoo P, Daniel SJ. Drooling quantification: Correlation of different techniques. Int J Pediatr Otorhinolaryngol 2015; 79: 1201-1205
- 74 Richards TM, Hurley T, Grove L. et al. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures. Oral Dis 2017; 23: 990-1000
- 75 Keam B, Kim SB, Shin SH. et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 2015; 121: 2612-2617
- 76 Goncalves PH, Heilbrun LK, Barrett MT. et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget 2017; 8: 32918-32929
- 77 Kim Y, Lee SJ, Lee JY. et al. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer 2017; 123: 1958-1964
- 78 Fushimi C, Tada Y, Takahashi H. et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 2018; 29: 979-984
- 79 Ressing M, Blettner M, Klug SJ. Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2009; 106: 456-463
- 80 Schmidt RL, Hunt JP, Hall BJ. et al. A systematic review and meta-analysis of the diagnostic accuracy of frozen section for parotid gland lesions. Am J Clin Pathol 2011; 136: 729-738
- 81 Liu CC, Jethwa AR, Khariwala SS. et al. Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2016; 154: 9-23
- 82 Stanek JJ, Khariwala SS. What Is the Utility of Fine-Needle Aspiration in Parotid Gland Neoplasms?. Laryngoscope 2019; 129: 1255-1256
- 83 Kim HJ, Kim JS. Ultrasound-guided core needle biopsy in salivary glands: A meta-analysis. Laryngoscope 2018; 128: 118-125
- 84 Strychowsky JE, Sommer DD, Gupta MK. et al. Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg 2012; 138: 541-547
- 85 Atienza G, Lopez-Cedrun JL. Management of obstructive salivary disorders by sialendoscopy: a systematic review. Br J Oral Maxillofac Surg 2015; 53: 507-519
- 86 Ramakrishna J, Strychowsky J, Gupta M. et al. Sialendoscopy for the management of juvenile recurrent parotitis: a systematic review and meta-analysis. Laryngoscope 2015; 125: 1472-1479
- 87 Schwarz Y, Bezdjian A, Daniel SJ. Sialendoscopy in treating pediatric salivary gland disorders: a systematic review. Eur Arch Otorhinolaryngol 2018; 275: 347-356
- 88 [Anonym] . Präoperative Evaluation erwachsener Patienten vor elektiven, nicht herz-thoraxchirurgischen Eingriffen. Gemeinsame Empfehlung der DGAI, DGCH und DGIM. Anästh Intensivmed 2017; 58: 349-364
- 89 Nickel C, Segarra D, Padhya T. et al. The evidence-based preoperative assessment for the otolaryngologist. Laryngoscope 2019;
- 90 Grosheva M, Horstmann L, Volk GF. et al. Frey’s syndrome after superficial parotidectomy: role of the sternocleidomastoid muscle flap: a prospective nonrandomized controlled trial. Am J Surg 2016; 212: 740
- 91 Hui Y, Wong DSY, Wong LY. et al. A prospective controlled double-blind trial of great auricular nerve preservation at parotidectomy. Am J Surg 2003; 185: 574-579
- 92 Grosheva M, Shabli S, Volk GF. et al. Sensation loss after superficial parotidectomy: A prospective controlled multicenter trial. Head Neck-J Sci Spec 2017; 39: 520-526
- 93 Grosheva M, Pick C, Granitzka T. et al. Impact of extent of parotidectomy on early and long-term complications: A prospective multicenter cohort trial. Head Neck 2019;
- 94 Albergotti WG, Nguyen SA, Zenk J. et al. Extracapsular dissection for benign parotid tumors: a meta-analysis. Laryngoscope 2012; 122: 1954-1960
- 95 Xie S, Wang K, Xu H. et al. PRISMA-Extracapsular Dissection Versus Superficial Parotidectomy in Treatment of Benign Parotid Tumors: Evidence From 3194 Patients. Medicine (Baltimore) 2015; 94: e1237
- 96 Lin Y, Wang Y, Ou Y. et al. Extracapsular dissection versus partial superficial parotidectomy for the treatment of benign parotid tumours. Int J Oral Maxillofac Surg 2019;
- 97 Foresta E, Torroni A, Di Nardo F. et al. Pleomorphic adenoma and benign parotid tumors: extracapsular dissection vs superficial parotidectomy – review of literature and meta-analysis. Oral Surg Oral Med Oral Pathol. Oral Radiol 2014; 117: 663-676
- 98 Colella G, Cannavale R, Chiodini P. Meta-analysis of surgical approaches to the treatment of parotid pleomorphic adenomas and recurrence rates. J Craniomaxillofac Surg 2015; 43: 738-745
- 99 O’Regan B, Bharadwaj G. Comparison of facial nerve injury and recovery rates after antegrade and retrograde nerve dissection in parotid surgery for benign disease: prospective study over 4 years. Br J Oral Maxillofac Surg 2011; 49: 286-291
- 100 Stankovic P, Wittlinger J, Timmesfeld N. et al. Antero- vs. retrograde nerve dissection in parotidectomy: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2018; 275: 1623-1630
- 101 Grosheva M, Klussmann JP, Grimminger C. et al. Electromyographic Facial Nerve Monitoring During Parotidectomy for Benign Lesions Does Not Improve the Outcome of Postoperative Facial Nerve Function: A Prospective Two-Center Trial. Laryngoscope 2009; 119: 2299-2305
- 102 Sood AJ, Houlton JJ, Nguyen SA. et al. Facial Nerve Monitoring during Parotidectomy: A Systematic Review and Meta-analysis. Otolaryng. Head Neck 2015; 152: 631-637
- 103 Graciano AJ, Fischer CA, Coelho GV. et al. Facial nerve dysfunction after superficial parotidectomy with or without continuous intraoperative electromyographic neuromonitoring: a prospective randomized pilot study. Eur Arch Otorhinolaryngol 2018; 275: 2861-2868
- 104 Roh JL, Park CI. A prospective, randomized trial for use of prednisolone in patients with facial nerve paralysis after parotidectomy. Am J Surg 2008; 196: 746-750
- 105 Lee KJ, Fee Jr. WE, Terris DJ. The efficacy of corticosteroids in postparotidectomy facial nerve paresis. Laryngoscope 2002; 112: 1958-1963
- 106 Infante-Cossio P, Prats-Golczer VE, Lopez-Martos R. et al. Effectiveness of facial exercise therapy for facial nerve dysfunction after superficial parotidectomy: a randomized controlled trial. Clin Rehabil 2016; 30: 1097-1107
- 107 Mier RJ, Bachrach SJ, Lakin RC. et al. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154: 1214-1218
- 108 Zeller RS, Davidson J, Lee HM. et al. Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions. Ther Clin Risk Manag 2012; 8: 25-32
- 109 Zeller RS, Lee HM, Cavanaugh PF. et al. Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Ther Clin Risk Manag 2012; 8: 15-23
- 110 Jost WH, Friedman A, Michel O. et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 2019;
- 111 Riley P, Glenny AM, Hua F. et al. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev 2017; 7: CD012744
- 112 Davies AN, Thompson J. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database Syst Rev 2015; CD003782
- 113 Li C, Wu F, Zhang Q. et al. Interventions for the treatment of Frey’s syndrome. Cochrane Database Syst Rev 2015; CD009959
- 114 Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev 2012; 11 CD008624
- 115 Ng L, Khan F, Young CA. et al. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2017; 1 CD011776
- 116 Kowalczyk DM, Jordan JR, Stringer SP. Cost-effectiveness of sialendoscopy versus medical management for radioiodine-induced sialadenitis. Laryngoscope 2018; 128: 1822-1828
- 117 Ong AA, Carroll WW, Nguyen SA. et al. Cost-effectiveness of transfacial gland-preserving removal of parotid sialoliths. Laryngoscope 2017; 127: 1080-1086
- 118 Kato MG, Erkul E, Nguyen SA. et al. Extracapsular Dissection vs Superficial Parotidectomy of Benign Parotid Lesions: Surgical Outcomes and Cost-effectiveness Analysis. JAMA Otolaryngol Head Neck Surg 2017; 143: 1092-1097
- 119 Hojjat H, Svider PF, Raza SN. et al. Economic Analysis of Using Free Fat Graft or Acellular Dermis to Prevent Post-parotidectomy Frey Syndrome. Facial Plast Surg 2018; 34: 423-428
- 120 Hojjat H, Svider PF, Raza SN. et al. ; Erratum: Economic Analysis of Using Free Fat Graft or Acellular Dermis to Prevent Post-parotidectomy Frey Syndrome. Facial Plast Surg . 2018. 34 e1
- 121 Guidubaldi A, Fasano A, Ialongo T. et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord 2011; 26: 313-319
- 122 Schroeder AS, Kling T, Huss K. et al. Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence. Neuropediatrics 2012; 43: 27-36
- 123 Vashishta R, Nguyen SA, White DR. et al. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg 2013; 148: 191-196
- 124 Banfi P, Ticozzi N, Lax A. et al. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir Care 2015; 60: 446-454
- 125 Man WH. Colen-de Koning JC, Schulte PF et al. The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. J Clin Psychopharmacol 2017; 37: 155-161
- 126 Sood S, McGurk M, Vaz F. Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130: S142-S149
- 127 Valstar MH, de Ridder M, van den Broek EC. et al. Salivary gland pleomorphic adenoma in the Netherlands: A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. Oral Oncol 2017; 66: 93-99
- 128 Andreasen S, Therkildsen MH, Bjorndal K. et al. Pleomorphic adenoma of the parotid gland 1985-2010: A Danish nationwide study of incidence, recurrence rate, and malignant transformation. Head Neck 2016; 38 Suppl 1 E1364-E1369
- 129 Schroder SA, Andersson M, Wohlfahrt J. et al. Incidence of sialolithiasis in Denmark: a nationwide population-based register study. Eur Arch Otorhinolaryngol 2017; 274: 1975-1981
- 130 Auvinen A, Hietanen M, Luukkonen R. et al. Brain tumors and salivary gland cancers among cellular telephone users. Epidemiology 2002; 13: 356-359
- 131 Brito-Zeron P, Acar-Denizli N, Zeher M. et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjogren Project Consortium. Ann Rheum Dis 2017; 76: 1042-1050
- 132 Brito-Zeron P, Acar-Denizli N, Ng WF. et al. How immunological profile drives clinical phenotype of primary Sjogren’s syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project). Clin Exp Rheumatol 2018; 36 Suppl): 112 102-112
- 133 Rosenthal MB, Frank RG, Li Z. et al. Early experience with pay-for-performance: from concept to practice. JAMA 2005; 294: 1788-1793
- 134 Matthes N. USA: Qualitätsbasierte Vergütung verbessert das Outcome. Dtsch Arztebl 2019; 116: A-248
- 135 Medicine Io . Crossing the Quality Chasm. A New Heath System for the 21st Century. Washington: National Academy Press; 2001
- 136 Quer M, Guntinas-Lichius O, Marchal F. et al. Classification of parotidectomies: a proposal of the European Salivary Gland Society. Eur Arch Otorhinolaryngol 2016; 273: 3307-3312